Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Multicenter Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of R21/Matrix-M Malaria Vaccine in African Infants With Different Immunization Schedules

NCT06879327 is registered in ClinicalTrials.gov with PATH as lead sponsor.

NCT NCT06879327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06879327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Multicenter Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of R21/Matrix-M Malaria Vaccine in African Infants With Different Immunization Schedules
Lead sponsor
PATH
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 30, 2025
Completion date
October 18, 2027
Enrollment
975 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malaria (plasmodium falciparum), malaria vaccines